RxDoctor Payments Data

Kelly Murtha

Physician Assistant · West Islip, NYNPI 1861044612

Payments from drug & device makers

$4,768in general payments, 2019–2025

Across 114 payments — averaging $41.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$551
  • Merck$450
  • E.r. Squibb & Sons, L.L.C.$353
  • Johnson & Johnson$346
  • Boehringer Ingelheim$336
  • plus $2K from 13 others

What the payments were for

  • Travel & lodging$4279%
  • Food & beverage$4,32291%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,768 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$20,809
Medicare patients
301
Services billed
593

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban907$1,093,696
EntrestoSacubitril/Valsartan366$514,929
XareltoRivaroxaban394$494,039
Repatha SureclickEvolocumab314$303,341
FarxigaDapagliflozin Propanediol151$208,613
JardianceEmpagliflozin106$161,167
Praluent PenAlirocumab96$101,753
BrilintaTicagrelor76$64,928
MultaqDronedarone Hcl18$35,168
VascepaIcosapent Ethyl58$32,631
Metoprolol Succinate1,965$31,351
OzempicSemaglutide27$25,123
NexlizetBempedoic Acid/Ezetimibe29$24,658
MounjaroTirzepatide24$23,908
VerquvoVericiguat17$23,709

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$110$1,093,696907 claims
NovartisEntresto$306$514,929366 claims
Johnson & JohnsonXarelto$346$494,039394 claims
AstraZenecaFarxiga, Brilinta$308$273,541227 claims
Boehringer IngelheimJardiance$336$161,167106 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$24$43,10054 claims
Sanofi-aventis U.S. LLCMultaq$23$35,16818 claims
Novo NordiskOzempic$302$25,12327 claims
MerckVerquvo$450$23,70917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in West Islip

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →